Below is Validea's guru fundamental report for TEMPUS AI INC (TEM). Of the 22 guru strategies we follow, TEM rates highest using our P/B Growth Investor model based on the published strategy of ...

Below is Validea's guru fundamental report for TEMPUS AI INC (TEM). Of the 22 guru strategies we follow, TEM rates highest using our P/B Growth Investor model based on the published strategy of ...

The high mortality rate is primarily driven by delayed diagnosis, rapid metastasis, and frequent recurrence. Tumor-derived exosomes (TEXs) have emerged as critical mediators in NSCLC progression, ...

Despite the deep selloff recently, I rank TEM a 'Strong Buy' with a target price of $62. There's now a great buy the dip opportunity. Since my last coverage, the stock had a stellar rally ...

In this article, we are going to take a look at where Tempus AI, Inc. (NASDAQ:TEM) stands against other AI news updates investors should not miss. Artificial intelligence is reshaping the job ...

to isolate exosomes, which were then characterized by nanoparticle tracking analysis (NTA) and transmission electron microscopy (TEM), followed by comprehensive metabolomic and proteomic analysis to ...

Institute of Soil and Water Resources and Environmental Science, College of Environmental and Resource Sciences, and Zhejiang Provincial Key Laboratory of Agricultural Resources and Environment, ...

Department of General Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China ...

The license agreement grants PranaX access to a core patent portfolio covering exosome manufacturing, engineering and therapeutic applications through a technology licensing agreement. This agreement ...

AI-driven healthcare solutions provider Tempus AI (TEM) has disclosed acquisition of Deep 6 AI, a precision research platform for healthcare and life sciences companies. This deal will integrate ...